This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333:1540–5. https://doi.org/10.1056/nejm199512073332305.
Bosly A, Coiffier B, Gisselbrecht C, Tilly H, Auzanneau G, Andrien F, et al. Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen. J Clin Oncol. 1992;10:1615–23. https://doi.org/10.1200/jco.1992.10.10.1615.
Cortelazzo S, Tarella C, Gianni AM, Ladetto M, Barbui AM, Rossi A, et al. Randomized trial comparing R-CHOP versus high-dose sequential chemotherapy in high-risk patients with diffuse large B-cell lymphomas. J Clin Oncol. 2016;34:4015–22. https://doi.org/10.1200/jco.2016.67.2980.
Chiappella A, Martelli M, Angelucci E, Brusamolino E, Evangelista A, Carella AM, et al. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. Lancet Oncol. 2017;18:1076–88. https://doi.org/10.1016/s1470-2045(17)30444-8.
Shi Y, Liu P, Zhou S, Yang J, Han X, He X, et al. Comparison of CBV, BEAM and BEAC high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation in non-Hodgkin lymphoma: Efficacy and toxicity. Asia Pac J Clin Oncol. 2017;13:e423–e429. https://doi.org/10.1111/ajco.12610.
Engert A, Schnell R, Küpper F, Reiser M, Engelhard M, Wilhelm M, et al. A phase-II study with idarubicin, ifosfamide and VP-16 (IIVP-16) in patients with refractory or relapsed aggressive and high grade non-Hodgkin’s lymphoma. Leuk Lymphoma. 1997;24:513–22. https://doi.org/10.3109/10428199709055588.
Tian C, Li Y, Liu S, Chen Z, Zhang Y, Yu Y, et al. Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin’s lymphoma patients. Sci Rep. 2021;11:4273 https://doi.org/10.1038/s41598-021-81944-8.
Oyan B, Koc Y, Ozdemir E, Kars A, Turker A, Tekuzman G, et al. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation. Biol Blood Marrow Transplant. 2005;11:688–97. https://doi.org/10.1016/j.bbmt.2005.05.014.
Galieni P, Troiani E, Bigazzi C, Mazzotta S, Ruggieri M, Pezzoni V, et al. Modified BEAM as conditioning regimen for lymphoma patients undergoing autologous hematopoietic stem cell transplantation. Bone Marrow Transplant. 2018;53:91–93. https://doi.org/10.1038/bmt.2017.206.
Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: final analysis of the prospective LNH87-2 protocol–a groupe d’Etude des lymphomes de l’Adulte study. J Clin Oncol. 2000;18:3025–30. https://doi.org/10.1200/jco.2000.18.16.3025.
Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, et al. Autologous transplantation as consolidation for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 2013;369:1681–90. https://doi.org/10.1056/NEJMoa1301077.
Colita A, Colita A, Bumbea H, Croitoru A, Orban C, Lipan LE, et al. LEAM vs. BEAM vs. CLV Conditioning Regimen for Autologous Stem Cell Transplantation in Malignant Lymphomas. Retrospective comparison of toxicity and efficacy on 222 patients in the first 100 days after transplant, On Behalf of the Romanian Society for Bone Marrow Transplantation. Front Oncol. 2019;9. https://doi.org/10.3389/fonc.2019.00892.
Acknowledgements
This work was supported by the Shanghai Science and Technology Committee (grant number: 21Y11909000), Shanghai Health Committee (grant number: 202140518), the Elite Project of Huadong hospital (HD1439).
Author information
Authors and Affiliations
Contributions
JM and YX were responsible for developing the conceptual framework of the study, designing and writing the protocol. JM, HY, and SS collected and analyzed data, conducted experiments, wrote and reviewed the paper. PC, MC, LS, MW, WQ, and WF conducted experiments. ZH contributed to the technical support. The authors read and approved the final manuscript.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Ma, J., Sun, S., Hu, Y. et al. Novel conditioning regimen in upfront autologous stem cell transplantation in high-risk DLBCL. Bone Marrow Transplant 57, 1612–1614 (2022). https://doi.org/10.1038/s41409-022-01766-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-022-01766-8